:

A Real-World Look: Are SGLT2 inhibitors safe in very elderly diabetic type 2 patients in real life?

Real-world studies indicate that SGLT2 inhibitors are generally safe and well-tolerated in very elderly diabetic type 2 patients, though special attention to potential side effects like volume depletion is warranted for fragile individuals. Addressing the safety of SGLT2 inhibitors for this population requires careful consideration of both the significant cardiorenal benefits and specific risks.